DICE Therapeutics Reports Second Quarter 2022 Financial Results and Recent HighlightsGlobeNewsWire • 08/11/22
Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@LillyPRNewsWire • 08/11/22
Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient ExperiencePRNewsWire • 08/08/22
Eli Lilly and Company (LLY) CEO Dave Ricks on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial ResultsPRNewsWire • 08/04/22
Eli Lilly Slashes Guidance After 'Significantly' Missing Quarterly Estimates; Shares DiveInvestors Business Daily • 08/04/22
Eli Lilly stock falls 3% after Q2 top and bottom line results miss Wall Street's forecastMarket Watch • 08/04/22
Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline AdvancementsPRNewsWire • 08/04/22
Earnings Preview: Eli Lilly (LLY) Q2 Earnings Expected to DeclineZacks Investment Research • 07/28/22